The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has come to result in a more immunogenic and effective response compared with conventional influenza vaccines in elderly and adults. - Trial 2014-004248-36
Access comprehensive clinical trial information for 2014-004248-36 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma Services AG and is currently status unknown. The study focuses on Influenza.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2014-004248-36
Trial Details
EU Clinical Trials Register • 2014-004248-36
The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has come to result in a more immunogenic and effective response compared with conventional influenza vaccines in elderly and adults.
Study Focus
Sponsor & Location
Novartis Pharma Services AG
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1. Percentage of subjects reporting solicited local and systemic AEs from day 1 to
ICD-10 Classifications
Influenza and pneumonia
Influenza due to identified seasonal influenza virus
Influenza with other manifestations, seasonal influenza virus identified
Influenza with pneumonia, seasonal influenza virus identified
Influenza due to identified zoonotic or pandemic influenza virus
Data Source
EU Clinical Trials Register
2014-004248-36
Non-Device Trial